Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under …

To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines
capable of eliciting broadly neutralizing antibody responses to CoVs. Here, we show that …

The emergence of SARS-CoV-2 variants, especially Beta and Delta, has raised concerns
about the reduced protection from previous infection or vaccination based on the original …

The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of
variants resistant to vaccine-induced immunity, has reignited debate over the need for …

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have
shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness …

Remarkable potency has been demonstrated for mRNA vaccines in reducing the global
burden of the ongoing COVID-19 pandemic. An alternative form of the mRNA vaccine is the …

Several COVID-19 vaccines have now been deployed to tackle the SARS-CoV-2 pandemic,
most of them based on messenger RNA or adenovirus vectors. The duration of protection …

As the COVID-19 pandemic continues, the authorization of vaccines for emergency use has
been crucial in slowing down the rate of infection and transmission of the SARS-CoV-2 virus …

(1) Background: As the COVID-19 pandemic enters its fourth year, it continues to cause
significant morbidity and mortality worldwide. Although various vaccines have been …